22. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281:1623–7.
23. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167–74.
24. Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995;31:1205–11.
25. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 1996;27:766–73.
26. Byhardt R, Brace K, Ruckdeschel J, Chang P, Martin R, Wiernik P. Dose and treatment factors in radiation-related pericardial effusion associated with the mantle technique for Hodgkin's disease. Cancer (Phila) 1975;35:795–802.
27. Totteman KJ, Pesonen E, Siltanen P. Radiation-related chronic heart disease. Chest 1983;83:875–8.
28. Cosset JM, Henry-Amar M, Pallae-Cosset B, Carde P, Girinski T, Tubiana M, et al. Percarditis and myocardial infarctions after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys 1991;21: 447–9.
29. Boivin JF, Hutchinson GB, Lubin JH, Mauch P. Corronary artery disease mortality in patients treated for Hodgkin's disease. Cancer (Phila) 1992;69:1241–7.
30. Corn BW, Trock BJ, Goodman RI. Irradiation-related ischemic heart disease. J Clin Oncol 1990;8:741–50.
31. Joensuu H. Acute myocardial infarction after heart irradiation in young patients with Hodgkin's disease. Chest 1989;95:388–90.
32. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003;21:2697–702.
33. Veeragandham RS, Goldin MD. Surgical management of radiation-induced heart disease. Ann Thorac Surg 1998;65:1014–9.

British Journal of Cancer (2007) 96, 492–498

www.bjcancer.com

Study of *p53* gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus

K Kaneko*[,1], A Katagiri[1], K Konishi[1], T Kurahashi[1], H Ito[1], Y Kumekawa[1], T Yamamoto[1], T Muramoto[1], Y Kubota[1], H Nozawa[1], R Makino[2], M Kushima[3] and M Imawari[1]

[1]Second Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan; [2]Clinical Research Laboratory, Showa University School of Medicine, Tokyo, Japan; [3]Department of Pathology, Showa University School of Medicine, Tokyo, Japan

Mutations of the *p53* gene are detected frequently in oesophageal dysplasia and cancer. It is unclear whether Lugol-unstained lesions (LULs) with non-dysplastic epithelium (NDE) are precursors of oesophageal squamous cell carcinoma (ESCC). To study the genetic alterations of NDE in the multistep process of oesophageal carcinogenesis, we determined the relationship between *p53* mutations and LULs-NDE. Videoendoscopy with Lugol staining was performed prospectively in 542 oesophageal cancer-free subjects. Lugol-unstained lesions were detected in 103 subjects (19%). A total of 255 samples, including 152 LULs (NDE, 137; dysplasia, 15) and 103 paired samples of normal staining epithelium, were obtained from 103 subjects. After extraction of DNA and polymerase chain reaction analysis, direct sequencing method was applied to detect mutations of the *p53* gene. The *p53* mutation was detected in five of 137 samples with LULs-NDE (4%) and in five of 15 samples with dysplasia (33%). A hotspot mutation was found in 20% of LULs-NDE with *p53* mutation and in 40% of dysplasia with *p53* mutation. In contrast, no *p53* mutations were found in 103 paired NDE samples with normal Lugol staining. In biopsy samples from oesophageal cancer-free individuals, the *p53* missense mutations containing a hotspot mutation were found in NDE, which was identified as an LUL. These findings suggest that some LULs-NDE may represent the earliest state of oesophageal squamous cell carcinoma in Japanese individuals.
British Journal of Cancer (2007) **96,** 492–498. doi:10.1038/sj.bjc.6603582 www.bjcancer.com

Keywords: *p53* mutation; Lugol staining; oesophagitis; dysplasia; endoscopy; precursor

Oesophageal squamous cell carcinoma (ESCC) is one of the most common carcinoma worldwide, with marked variation in its incidence rate among different countries, distinct geographic areas, and different ethnic groups (Parkin *et al*, 1988). Among oesophageal cancers in Japanese patients, 95% are squamous cell carcinomas (Registration Committee for Esophageal Cancer). In Western countries and Japan, heavy cigarette smoking and alcohol intake are the risk factors, whereas in the developing countries, exposure to dietary carcinogens and nutritional deficiencies are believed to be the major aetiologic factors (Yang, 1980; Von Rensburg, 1981; Parkin *et al*, 1988; Yokoyama *et al*, 1995). However, results from previous studies suggest that malignant transformation of human oesophageal epithelium is a multistage progressive process (Yang, 1980; Yang and Qiu, 1987; Qiu and Yang, 1988; Wang *et al*, 1990; Bennett *et al*, 1992; Wang *et al*, 1993; Greenblatt *et al*, 1994).

*Correspondence: Dr K Kaneko, Second Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan;
E-mail: gikaneko@med.showa-u.ac.jp
Received 25 July 2006; revised 15 November 2006; accepted 12 December 2006

Characterisation of human oesophageal precancerous lesions at the molecular level is of critical importance to our understanding of the aetiology of ESCC and to the identification of useful biomarkers for prevention studies of that disease. Mutation analyses among high-risk Chinese populations have demonstrated that *p53* gene mutations occur at an early stage of oesophageal carcinogenesis, both in the setting of basal cell hyperplasia (BCH) and in dysplastic lesions (Bennett *et al*, 1992; Wang *et al*, 1993; Gao *et al*, 1994; Jaskiewicz and De Groot, 1994; Parenti *et al*, 1995). An early indicator of abnormality in individuals predisposed to ESCC is an increased proliferation of the oesophageal epithelial cells, morphologically manifested as BCH, dysplasia, and cancer *in situ*. Most of these lesions could be considered as precancerous lesions because of the presence of *p53* mutations (Yang, 1980; Yang and Qiu, 1987; Qiu and Yang, 1988; Wang *et al*, 1990; Mandard *et al*, 2000). But it is under debate whether BCH is a precancerous lesion for ESCC or not, as no hotspot mutations of the *p53* gene were found in BCH samples (Shi *et al*, 1999).

Although endoscopic detection for early ESCC is extremely important because of excellent 5-year survival rate (Yoshinaka *et al*, 1991; Kumagai *et al*, 1993), two-thirds of oesophageal intraepithelial carcinomas have been overlooked by conventional endoscopy alone (Sugimachi *et al*, 1989). A simple technique of spraying Lugol solution in the oesophagus is highly sensitive for identifying dysplasia and intraepithelial carcinoma (Mori *et al*,

1993; Meyer *et al*, 1997; Dawsey *et al*, 1998). According to the Lugol staining pattern, completely 'unstained' areas were found in approximately 90% of high-grade dysplasia and carcinoma, whereas approximately 90% of staining areas, which were less intensely stained than normally stained epithelium, were non-dysplastic lesions and the remaining 10% were dysplasia (Mori *et al*, 1993). Therefore, Lugol-unstained lesions (LULs) are detectable not only in dysplasias and carcinomas but also in non-dysplastic areas, for example with oesophagitis, or in the setting of Barrett's oesophagus (Sugimachi *et al*, 1989; Dawsey *et al*, 1998). In contrast, Lugol staining methods were not used in most studies regarding *p53* mutational status in oesophageal precancerous lesions such as dysplasia, BCH, and esophagitis (Yang and Qiu, 1987; Qiu and Yang, 1988; Wang *et al*, 1990; Bennett *et al*, 1992; Wang *et al*, 1993; Gao *et al*, 1994; Greenblatt *et al*, 1994; Jaskiewicz and De Groot, 1994; Parenti *et al*, 1995; Shi *et al*, 1999; Mandard *et al*, 2000).

Resected specimens from cancer patients were used in the analysis of the *p53* mutations in the previous studies (Yang, 1980; Yang and Qiu, 1987; Qiu and Yang, 1988; Wang *et al*, 1990; Shi *et al*, 1999; Mandard *et al*, 2000). Little information is available regarding the *p53* mutational status in the Lugol-unstained lesions with non-dysplastic epithelium (LULs-NDE) of oesophageal cancer-free subjects. To determine the genetic alterations in the early stage of oesophageal carcinogenesis, oesophageal cancer-free subjects should be selected. Endoscopic detection of oesophageal precancerous lesions and molecular diagnosis is of clinical importance to identify high-risk patients and to prevent the development of ESCC. We carried out a prospective study of the *p53* mutational status of both LULs-NDE and paired samples of normal Lugol staining areas from endoscopic biopsy samples obtained after spraying the oesophagus with Lugol solution.

MATERIALS AND METHODS

Study design

To investigate whether LULs-NDE were related to the carcinogenesis of oesophageal squamous epithelium or not, the *p53* mutational status in LULs-NDE was analysed prospectively. Secondary end points were to elucidate whether BCH is related to oesophageal carcinogenesis through the *p53* mutational status and examine malignant potential in multiple LULs. Recruited subjects were composed of oesophageal cancer-free individuals who visited our hospital for a health checkup between April 1999 and March 2001. Subjects were recruited on the basis of the following criteria: male and female individuals, age in the range of 20–80 years, the subjects performance status being 'zero' according to Eastern Cooperative Oncology Group (ECOG), and the subjects with no symptoms of dysphagia, abdominal pain, chest and/or back pain, or vomiting were eligible. As LULs can be caused by reflux oesophagitis, subjects with heartburn and those receiving proton pump inhibitor therapy were excluded. Subjects who had active malignant disease, and who had undergone oesophagectomy or chemoradiotherapy for ESCC, were excluded. After endoscopic observation, subjects who had oesophageal varices, Barrett's oesophagus, or reflux oesophagitis were also excluded. Although heavy cigarette smoking and alcohol intake are the major risk factors of ESCC, whether the oesophageal precancerous lesions are caused by such daily consumption or not is uncertain. Therefore, the subjects were not selected based on risk factors such as smoking and alcohol drinking. Participants were interviewed using structured questionnaires, which included queries about smoking and drinking status after recruitment. All subjects gave informed consent for participation in the study. The study protocol was approved by the Human Ethics Review Committee of Showa University School of Medicine.

Patient population

A total of 599 subjects were recruited: 542 subjects matched the recruitment criteria and 42 subjects were excluded from the study. The reasons for exclusion were symptom-free reflux oesophagitis in 15 subjects, Barrett's oesophagus in five subjects, gastric carcinoma in one subject, and rejection to the study in 21 subjects. The mean age was 61 years, ranging from 20 to 80 years, and the male to female ratio was 274/268. Of the 542 subjects, 157 (29%) and 130 (24%) had daily consumption of cigarette and alcohol, respectively.

Endoscopic examination

Videoendoscopy (Q240, Olympus, Tokyo, Japan) following Lugol solution spraying was performed on all oesophageal cancer-free subjects who matched the recruitment criteria. After ordinary endoscopic observation, 5–10 ml of 2.0% glycerin-free Lugol's iodine solution, which was a brown liquid consisting of 2.0 g potassium iodine and 4.0 g iodine in 100 ml distilled water, was sprayed from the gastroesophageal junction to the upper oesophagus using a plastic spray catheter (washing tube PW-5L; Olympus, Tokyo, Japan) passed through the biopsy channel of the endoscope. The whole oesophagus was observed again and epithelial areas were categorised as unstained, normally stained, or overstained. We defined LULs as those areas either staining less intensely than normally stained epithelium or completely unstained (Figure 1A–C); this group of lesions included carcinoma, dysplasia, and oesophagitis. When 10 and more than 10 LULs were detected in one endoscopic view, we defined them as multiple LULs (Figure 1D). Biopsies were taken under endoscopic guidance for LULs and paired normal Lugol staining background epithelium. The background epithelium specimens were obtained 1–5 cm away from LULs. We confirmed that samples were correctly taken from LULs during endoscopic observation. Histologic diagnosis among normal epithelium, oesophagitis, BCH, dysplasia, and carcinoma was made according to previously described definitions (Dawsey *et al*, 1994). Histologic features were evaluated by a pathologist in our hospital.

DNA extraction

Ten 2-μm-thick sections were obtained from each archival block of formalin-fixed and paraffin-embedded dysplastic and non-dysplastic tissue. One section of each block was stained with haematoxylin and eosin. The percentage of neoplastic cells was estimated by light microscopic evaluation, and the samples containing a minimum of 60% dysplastic cells were chosen. DNA samples were extracted by the ethanol/xylene method from the remaining nine sections (Goelz *et al*, 1985).

Analysis of the *p53* gene

Specimens were mixed with 50 μl of digestion buffer (0.04% proteinase K, 10 mM Tris-HCl at pH 8.0, 1 mM EDTA, and 1% Tween 20) and incubated at 37°C for 18 h. The DNA fragments were analysed for mutations in *p53* exons 5, 6, 7, and 8, as described in our previous report (Makino *et al*, 2000). Primers used for polymerase chain reaction (PCR) amplification of the *p53* gene were as follows: for exon 5, 5′-TTCACTTGTGCCCTGATTTC-3′ and 5′-CTCTCCAGCCCCAGCTGCTC-3′; for exon 6, 5′-ATTCCT-CACTGATTGCTCC-3′ and 5′-TCCTCCCAGAGACCCCAGTT-3′; for exon 7, 5′-ACAGGTCCTCCCCAAGGCGCA-3′ and 5′-TGTGCA GGGTGGCAAGTGGCT-3′; for exon 8, 5′-GTAGGACCTGATTTCC TTACTGCC-3′ and 5′-CTTGGTCTCCTCCACCGCTTCTTG-3′. Polymerase chain reaction conditions were set as described in our report (Makino *et al*, 2000). The PCR products were purified and directly sequenced using a 3100 sequencing machine (Applied



Figure 1 (**A**) Endoscopic findings of a Lugol-unstained lesion. This lesion was completely unstained. The lesion was oval and 4 mm in diameter. (**B**) Endoscopic findings of a Lugol-unstained lesion. This lesion was completely unstained. The lesion was irregular in shape and 6 mm in diameter. (**C**) Endoscopic findings of normal Lugol staining epithelium without a Lugol-unstained lesion. (**D**) Endoscopic findings of multiple Lugol-unstained lesions. Many irregular lesions that were stained less intensely than normal Lugol staining epithelium were located in one endoscopic view.



Figure 2 Mutation of the *p53* gene at codon 175 in exon 5 was shown in electropherograms. Base changed from CGC to CAC (black arrow). wt. wild type; mut. mutation.

Biosystems, Foster City, CA, USA). Peak patterns were analysed using Sequencing Analysis Software (Applied Biosystems, Foster City, CA, USA), and mutations and amino-acid changes were identified (Figure 2). To ensure reproducibility of our data, direct sequencing was performed at least twice in DNA samples.

Statistical analysis

As LULs were found in approximately 20% of 1000 patients undergoing routine endoscopy in our previous experience, sample size was estimated to be 500 patients to collect at least 100 patients with LULs. To avoid bias, the data regarding the detection of *p53* mutation in LULs and their paired normal Lugol staining areas were re-identified for genetic and clinicopathologic analyses. These data were then matched after the genetic and clinicopathologic analyses were completed. The significance of differences between the two groups was assessed by the χ^2 test or Wilcoxon rank-sum test. *P*-value of less than 0.05 was considered significant.

RESULTS

Characteristics of subjects

Out of 542 subjects, LULs were found in 103 (19%).The mean age was 62 years, ranging from 25 to 80 years, and the male to female ratio was 63/50. Of the 103 subjects, 35 (34%) and 31 (30%) had a daily habit of cigarette smoking and alcohol drinking, respectively. No significant difference in the frequency of daily cigarette smoking ($P=0.213$) or alcohol ($P=0.107$) consumption was seen between the subjects with LULs and those without.

Histologic and clinicopathologic findings

The samples of LULs consisted of 137 NDE and 15 dysplastic samples, whereas no dysplastic samples were detected in the normal Lugol staining samples (Table 1). Whereas the histologic finding in all samples of LULs-NDE was oesophagitis, 78% of the 103 normal Lugol staining epithelium samples were oesophagitis ($P<0.0001$). The histologic grade of dysplastic samples was

low-grade in nine of 15 (60%) samples and high-grade in six (40%) samples.

The clinicopathologic findings of LULs-NDE and dysplasia are shown in Table 2. Most LULs-NDE and dysplasia also were located in the middle third of the thoracic oesophagus, as most invasive ESCCs were located in the same portion (Registration Committee for Esophageal Cancer). The characteristics of LULs-NDE were minute size (<5 mm in diameter), oval shape, and location in the middle third of the oesophagus.

Table 1 Histologic findings of biopsy samples from 103 oesophageal cancer-free patients

	Lugol-unstained lesions	Normal Lugol staining epithelium	*P*-value
Number of samples	152	103	
Histologic findings			
Dysplasia	15	—	
Oesophagitis	137	80	<0.0001
Normal epithelium	—	23	
Basal cell hyperplasia			
Present	3	2	0.986
Absent	149	101	

Table 2 Clinicopathologic characteristics and presence of *p53* mutation of LUL-NDE and dysplasia

	LUL-NDE ($n=137$)	Dysplasia ($n=15$)	*P*-value
Mean size (mm)	4	9	0.032
Range (mm)	1–6	5–20	
Shape of LUL			
Oval	108	5	<0.0001
Irregular	29	10	
Location			
Upper third	19	1	0.441
Middle third	90	9	
Lower third	28	5	
P53 mutation			
Present	5	5	<0.0001
Absent	132	10	
Hotspot mutation (10 samples with p53 mutation)			
Present	1	2	0.490
Absent	4	3	

LUL-NDE = Lugol-unstained lesion with non-dysplastic epithelium; location = location of the oesophagus.

Mutation of the *p53* gene

p53 mutation was detected in five of the 137 LULs-NDE samples, whereas no *p53* mutations were found in normal Lugol staining epithelium samples (Table 2). The mutations of the *p53* gene in LULs-NDE were one in exon 6, three in exon 7, and one in exon 8, and all were missense mutations (Table 3). A 'hotspot' mutation at codon 273 was found in one of the five LULs-NDE. A *p53* mutation was found in three of nine subjects (33%) with low-grade dysplasia and two of six subjects (33%) with high-grade dysplasia. The mutations of the *p53* gene in dysplastic lesions were three in exon 5 and two in exon 6, and four were missense mutations and one was a nonsense mutation resulting in insertion of a stop codon. A hotspot mutation at codon 175 was found in two of five dysplasia samples and these two samples were low-grade dysplasia.

In contrast, 22 (16%) of 137 LULs-NDE showed squamous atypia (Table 4). *p53* mutation was found in one (4.5%) of 22 LULs-NDE with squamous atypia (Figure 3A), and in four (3.5%) of 115 LULs-NDE without squamous atypia (Figure 3B and Table 4). Approximately 80% of the normal Lugol staining epithelium samples were oesophagitis, whereas no squamous atypia was found in normal epithelium samples.

Basal cell hyperplasia was present in 2% of LUL samples and 2% of normal Lugol staining epithelium samples alone (Table 1). Notably, *p53* mutations were not found in both LULs-NDE and normal Lugol staining epithelium samples with BCH (Table 4).

Multiple LULs

A single or few LULs were detected in 98 (95%) subjects and multiple LULs were found in five (5%) subjects (Table 5). Although multiple LULs were found in only five (0.9%) of the 542 subjects, three of the five subjects with multiple LULs (60%) had dysplasia ($P=0.003$; Table 5).

No significant difference was seen in the occurrence of *p53* mutations between subjects with single or few LULs and multiple LULs (Table 5). Although the same mutation in exon 6 at (codon 218) was found in both dysplasia and LULs-NDE in case 2 with multiple LULs-NDE (Table 3), the two lesions were independent and were not contiguous. One lesion was located in the middle oesophagus, with dysplasia of 6-mm diameter area; the other was located in the lower oesophagus, with LUL-NDE of 4-mm diameter area.

Table 3 Mutation of the *p53* gene in patients with Lugol-unstained lesions

Case	Age/sex	Histology	Size (mm)	p53	Ex	Codon	BC	AAC
1	52/M	itis	3	P	7	242	TGC→TCC	K→S
2	53/M	sev, dys.	6	P	6	218	GTG→GAG	V→E
		itis	4	P	6	218	GTG→GAG	V→E
		itis	3	A				
3	78/M	mod, dys.	0	P	6	192	CAG→TAG	*
4	71/M	mild, dys.	8	P	5	175	CGC→CAC	R→H
5	53/F	mild, dys.	6	P	5	175	CGC→GGC	R→G
6	63/M	sev, dys.	13	P	5	184	GAT→AAT	D→N
7	68/F	itis	3	P	7	241	TCC→TAC	S→Y
8	75/M	itis	4	P	8	273	CGT→TGT	R→C
		itis	2	A				
9	60/F	itis	4	P	7	239	AAC→GAC	N→D
		itis	5	A				
		itis	3	A				

itis = oesophagitis; dys, dysplasia; sev = severely; mod = moderately; P = presence of a *p53* mutation; A = absence of a *p53* mutation; EX = exon; BC = base change; AAC = amino-acid change; * = stop codon.

Table 4 Relationship between presence of *p53* mutation and BCH or squamous atypia in 137 LULs-NDE

	p53 mutation Present ($n=5$)	p53 mutation Absent ($n=132$)	*P*-value
Squamous atypia			
Present ($n=22$)	1	21	0.807
Absent ($n=115$)	4	111	
BCH			
Present ($n=3$)	0	3	0.733
Absent ($n=134$)	5	129	

LULs-NDE = Lugol-unstained lesions with non-dysplastic epithelium; BCH = basal cell hyperplasia.



Figure 3 (**A**) Histologic findings of squamous atypia in a Lugol-unstained lesion with *p53* mutation. The region with squamous atypia was a small portion in contact with the basal cell layer. In the region, the nucleus was slightly enlarged, whereas pleomorphism and hyperchromasia were not seen. According to histological criteria of the Chinese group, the findings of slightly mononuclear enlargement having neither pleomorphism nor hyperchromasia were insufficient for diagnosis of dysplasia, and was decided as inflammation containing atypia. (**B**) Histologic findings of no squamous atypia in a Lugol-unstained lesion with *p53* mutation. Of the five Lugol-unstained lesions with non-dysplastic epithelium (LULs-NDE) containing *p53* mutation, squamous atypia was not found in four LULs-NDE.

DISCUSSION

This study is aimed to evaluate whether LULs-NDE are related to the carcinogenesis of oesophageal squamous epithelium or not, and *p53* mutational status in LULs-NDE is analysed on the basis of molecular events in the progressive process of carcinoma. As *p53* mutation is a well-known sequence in dysplasia and carcinoma, this biomarker was determined to identify the precancerous lesions in the study. The unique observation in this prospective study is that missense mutations of the *p53* gene were found in LULs-NDE, although no *p53* mutations were found in paired normally Lugol-stained non-dysplastic epithelium in subjects with LULs-NDE. The results strongly suggest that some of the LULs-NDE can progress to dysplastic lesions through *p53* alterations and support the hypothesis that some of 'Lugol-unstained non-dysplastic areas' in Japanese individuals without reflux esophagitis play an important role in oesophageal carcinogenesis.

Mutations of the *p53* tumour suppressor gene are the most common genetic abnormalities in solid human cancers (Nigro *et al*, 1989; Hollstein *et al*, 1990; Lane, 1992; Vogelstein *et al*, 2000; Vousden and Lu, 2002; Oliver *et al*, 2004). Missense mutations are found in 78% of the 6177 somatic *p53* mutations in exons 5–8 (Hussain and Harris, 1999), suggesting a correlation between the degree of evolutionary diversity and the structural or functional importance of individual amino-acid residues (Greenblatt *et al*, 1994). The change of protein structure or function caused by the individual amino-acid residues in LULs-NDE might be early molecular events in carcinogenesis. In contrast, *p53* gene mutations have been proposed to be concentrated in six hotspots (Hainaut *et al*, 1997; Hussain and Harris, 1999; Vikhanskaya *et al*, 2005). Based on the updated *p53* Gene Mutation Database containing 5961 mutations, codons 175, 245, 248, 249, 273, and 282 have been identified as mutation hotspots in human cancers, and the incidence of the hotspot mutations is specific molecular alterations in solid human cancers (Hainaut *et al*, 1997). A hotspot can identify a relationship between the mutation, protein structure and function, and carcinogenesis (Hsu *et al*, 1991; Cho *et al*, 1994; Greenblatt *et al*, 1994; Tornaletti and Pfeifer, 1994). Furthermore, hotspot mutations in carcinomas represent protein alterations that provide a selective growth advantage to the cell, and missense mutations at six hotspots account for 25–30% of the mutations (Greenblatt *et al*, 1994; Hainaut *et al*, 1997; Hussain and Harris, 1999; Ito *et al*, 2000). Therefore, protein alterations that provide a selective growth advantage to the cell would have already occurred in cells of LULs-NDE before histologic transformation into dysplastic cells. Mutations at codon 175 and 273 have been shown to have transforming frequencies that are 22- and eight-fold, respectively, the basal level of wild-type p53 protein (Zambetti and Levine, 1993). From our results, the LUL-NDE or low-grade dysplasia containing mutations with high transforming activities, such as codon 175 and 273 mutations, might have growth advantages favouring progression to invasive ESCC with the acquisition of other genetic changes, and may acquire malignant potential before morphologically manifested cell proliferation at an early molecular level of carcinogenesis.

One group has proposed that BCH is an early indicator of oesophageal carcinogenesis (Yang, 1980; Yang and Qiu, 1987; Qiu and Yang, 1988; Wang *et al*, 1990). Wang *et al* (1996) reported that BCH can be found in 69% of biopsy samples in symptom-free patients and that *p53* mutations can be found in BCH and dysplastic samples, whereas no hotspot mutations are contained in these mutations (Shi *et al*, 1999). We also identified the histologic findings of BCH in LULs-NDE and the paired normal Lugol staining area according to histologic criteria used in the Chinese group (Dawsey *et al*, 1994), whereas prevalence of BCH was low in our Japanese subjects and no *p53* mutations were found. We do not believe that the role of BCH is related to oesophageal carcinogenesis in the Japanese population. In contrast, we did not suggest that the daily cigarette or alcohol consumption was directly related to the occurrence of LULs-NDE in this study despite high risk factors in patients with ESCC.

Using Lugol solution spraying methods, as the normal squamous epithelium contains glycogen that interacts with the

Table 5 Presence of dysplasia and *p53* mutation between single or few and multiple Lugol-unstained lesions in 103 patients

	Single or few LULs ($n=98$)	Multiple LULs ($n=5$)	*P*-value
Dysplasia			
Present	12 (12%)	3 (60%)	0.003
Absent	86 (88%)	2 (40%)	
p53 mutation			
Present	8 (8%)	1 (20%)	0.361
Absent	90 (92%)	4 (80%)	

LULs = Lugol-unstained lesions.

iodine of Lugol's solution, normal epithelium of the oesophagus becomes uniformly greenish brown (Sugimach *et al*, 1991; Katagiri *et al*, 2004). Dysplastic and inflammatory epithelia of the oesophagus are not stained, as the region showing dysplasia and oesophagitis has a reduced or no glycogen content (Sugimach *et al*, 1991). Therefore, these minute lesions that were not identifiable by conventional endoscopic observation become visible when Lugol's solution is used. There is a high possibility that inflammation having a reduction in glycogen content is related to the initiation of oesophageal carcinogenesis because no squamous atypia and no *p53* mutations are found in normal Lugol staining areas with sufficient glycogen content. Squamous atypia would be transitional lesions from oesophagitis to dysplasia.

Although the prevalence of multiple LULs was low in oesophageal cancer-free subjects (0.9%), dysplasia occurred frequently in subjects with multiple LULs (60%). Muto *et al* (2002) reported that multiple LULs were found in 27% of head and neck cancer patients, and secondary ESCCs were found in 72% of such cancer patients with multiple LULs. They provided essential information about field cancerisation and malignant potential with respect to multiple LULs. The field cancerisation phenomena proposed that multiple squamous cell carcinomas occurred either simultaneously with the primary lesion (synchronous) or after a period of time (metachronous) in the oesophagus and the head and neck region. There is a possibility that widespread epithelial oncogenic alterations were found in patients with multiple LULs. In case 2, the same mutation at codon 218 was found in both LUL-NDE and dysplastic lesion, whereas *p53* mutation was not detected in background normal Lugol staining epithelium. The *p53* mutational status, in this case, reflects the phenomena of field cancerisation, which can be considered as high malignant potential.

The *p53* missense mutations containing a hotspot mutation were found in LULs-NDE in oesophageal cancer-free individuals without reflux oesophagitis. The finding suggests that LUL-NDE is an initial lesion for oesophageal carcinogenesis, and that the role of BCH is less clear for oesophageal carcinogenesis in Japanese individuals. The characteristic findings of high-risk population of oesophageal carcinoma were evaluated by genetic analyses, because it appeared that we emphasise the importance of both endoscopic detection of LUL-NDE and molecular diagnosis. We concluded that the understanding of aetiology in human oesophageal precursor at the molecular level could provide essential information about the identification of useful biomarkers for prevention studies.

ACKNOWLEDGEMENTS

This work was supported by a Grant-in-Aid for Cancer Research (14-3) from the Ministry of Health, Labour and Welfare, and a Showa University Grant-in-Aid for Innovative Collaborative Research Projects and a Special Research Grant-in-Aid for Development of Characteristic Education from the Japanese Ministry of Education, Culture, Sports, Science and Technology of Japan. We thank Takahiko Tonoike, Yoshiko Tsuda, and Mitsuharu Kanoh (Department of Pathology, Showa University School of Medicine) for their excellent technical support in histology.

REFERENCES

Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, Kusters I, Resau JH, Trump BF, Lane DP (1992) p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. *Cancer Res* **52**: 6092–6097

Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. *Science* **265**: 346–355

Dawsey SM, Fleischer DE, Wang GQ, Zhou B, Kidwell JA, Lu N, Lewin KJ, Roth MJ, Tio TL, Taylor PR (1998) Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. *Cancer* **83**: 220–231

Dawsey SM, Lewin KJ, Liu FS, Wang GQ, Shen Q (1994) Esophageal morphology from Linxian, China. Squamous histologic findings in 754 patients. *Cancer* **73**: 2027–2037

Gao H, Wang LD, Zhou Q, Hong JY, Huang TY, Yang CS (1994) p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. *Cancer Res* **54**: 4342–4346

Goelz SE, Hamilton SR, Vogelstein B (1985) Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. *Biochem Biophys Res Commun* **130**: 118–126

Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer Res* **54**: 4855–4878

Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R (1997) Database p53 gene somatic mutation in human tumors and cell lines: updated complication and future prospects. *Nucleic Acid Res* **25**: 151–157

Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC (1990) Frequent mutation of the p53 gene in human esophageal cancer. *Proc Natl Acad Sci USA* **87**: 9958–9961

Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. *Nature* **350**: 427–428

Hussain SP, Harris CC (1999) p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. *Mutat Res* **428**: 23–32

Ito T, Kaneko K, Makino R, Ito H, Konishi K, Kurahashi T, Kitahara T, Mitamura K (2000) Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. *J Gastroenterol* **36**: 303–311

Jaskiewicz K, De Groot K (1994) p53 gene mutants expression, cellular proliferation and differentiation in esophageal carcinoma and non-cancerous epithelium. *Anticancer Res* **14**: 137–140

Katagiri A, Kaneko K, Konishi K, Ito H, Kushima M, Mitamura K (2004) Lugol staining pattern in background epithelium of patients with esophageal squamous cell carcinoma. *Hepatogastroenterology* **51**: 713–717

Kumagai Y, Makuuchi H, Mitomi T, Ohmori T (1993) A new classification system for early carcinomas of the esophagus. *Dig Endosc* **15**: 5139–5150

Lane DP (1992) p53 guardian of the genome. *Nature (London)* **358**: 15–16

Makino R, Kaneko K, Kurahashi T, Matsumura T, Mitamura K (2000) Detection of mutation of the p53 gene with high sensitivity by fluorescence-based PCR-SSCP analysis using low-pH buffer and an automated DNA sequencer in a large number of DNA samples. *Mutat Res* **452**: 83–90

Mandard AM, Hainaut P, Hollstein M (2000) Genetic steps in the development of squamous cell carcinoma of the esophagus. *Mutat Res* **462:** 335–342

Meyer V, Burtin P, Bour B, Blanchi A, Cales P, Oberti F, Person B, Croue A, Dohn S, Benoit R, Fabiani B, Boyer J (1997) Endoscopic detection of early esophageal cancer in a high-risk population: does Lugol staining improve videoendoscopy? *Gastrointest Endosc* **45:** 480–484

Mori M, Adachi Y, Matsushima T, Matsuda H, Kuwano H, Sugimachi K (1993) Lugol staining pattern and histology of esophageal lesions. *Am J Gastroenterol* **88:** 701–705

Muto M, Nakane M, Hitomi Y, Yoshida S, Sasaki S, Yoshida S, Ebihara S, Esumi H (2002) Association between aldehyde dehydrogenase gene polymorphisms and the phenomenon of field cancerization in patients with head and neck cancer. *Carcinogenesis* **23:** 1759–1765

Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Sevilee P, Glver T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumor types. *Nature (London)* **342:** 705–708

Oliver M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC (2004) TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. *IARC Sci Publ* **157:** 247–270

Parenti AR, Rugge M, Frizzera E, Ruol A, Noventa F, Ancona E, Ninfo V (1995) p53 overexpression in the multistep process of esophageal carcinogenesis. *Am J Surg Pathol* **19:** 1418–1422

Parkin DM, Laara E, Muir CS (1988) Estimates of the worldwide frequency of 16 major cancers in 1980s. *Int J Cancer* **41:** 184–197

Qiu SL, Yang GR (1988) Precursor lesions of esophageal cancer in high-risk populations in henan province, China. *Cancer* **62:** 551–557

Registration Committee for Esophageal Cancer (ed) Comprehensive registry of esophageal cancer in Japan. *The Japan Society for Esophageal Diseases*, http://plaza.umin.ac.jp/_~jsed/

Shi ST, Yang GY, Wang LD, Xue Z, Feng B, Ding W, Xing EP, Yang CS (1999) Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. *Carcinogenesis* **20:** 591–597

Sugimach K, Tsutsui S, Kitamura K, Morita M, Mori M, Kuwano H (1991) Lugol stain for intraoperative determination of the proximal surgical margin of the esophagus. *J Surg Oncol* **46:** 226–229

Sugimachi K, Ohno S, Matsuda H, Mori M, Matsuoka H, Kuwano H (1989) Clinicopathologic study of early stage esophageal carcinoma. *Surgery* **105:** 706–710

Tornaletti S, Pfeifer GP (1994) Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. *Science* **263:** 1436–1438

Vikhanskaya F, Siddique MM, Lee MK, Broggini M, Sabapathy K (2005) Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. *Clin Cancer Res* **11:** 4348–4356

Vogelstein B, Lane D, Levine AJ (2000) Surface the p53 network. *Nature* **408:** 307–310

Von Rensburg SJ (1981) Epidemiologic and ditary evidence for a specific nutritional predisposition to esophageal cancer. *J Natl Cancer Inst* **67:** 243–251

Vousden KH, Lu X (2002) Live or die: the cell's response to p53. *Nat Rev Cancer* **2:** 594–604

Wang LD, Hong JY, Qiu SL, Gao H, Yang CS (1993) Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. *Cancer Res* **53:** 1783–1787

Wang LD, Lipkin M, Qiu SL, Yang GR, Yang CS, Newmark HL (1990) Labeling index and labeling distribution of cells in the esophageal epithelium in individuals at increased risk for esophageal cancer in Huixian, China. *Cancer Res* **50:** 2651–2653

Wang LD, Zhou Q, Hong JY, Qiu SL, Yang CS (1996) p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China. *Cancer* **77:** 1244–1249

Yang CS (1980) Research on esophageal cancer in China: a review. *Cancer Res* **40:** 2633–2644

Yang GR, Qiu SL (1987) Endoscopic surveys in high-risk populations for esophageal cancer in China with special reference to precursors of esophageal cancer. *Endoscopy* **19:** 91–95

Yokoyama A, Ohmori T, Makuuchi H, Maruyama K, Okuyama K, Takahashi H, Yokoyama T, Yoshino K, Hayashida M, Ishii H (1995) Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosal iodine staining. *Cancer* **76:** 928–934

Yoshinaka H, Shimazu H, Fukumoto T, Baba M (1991) Superficial esophageal carcinoma: a clinicopathological review of 59 cases. *Am J Gastroenterol* **86:** 1413–1418

Zambetti GP, Levine AJ (1993) A comparison of the biological activities of wild-type and mutant p53. *FASEB J* **7:** 855–865

Jpn J Clin Oncol 2006;36(4)218–223
doi:10.1093/jjco/hyl020

Phase I/II Study of Oxaliplatin with Weekly Bolus Fluorouracil and High-Dose Leucovorin (ROX) As First-Line Therapy for Patients with Colorectal Cancer

Yasuhide Yamada[1], Atsushi Ohtsu[2], Narikazu Boku[3], Yoshinori Miyata[4], Yasuhiro Shimada[1], Toshihiko Doi[2], Kei Muro[1], Manabu Muto[2], Tetsuya Hamaguchi[1], Kiyomi Mera[2], Tomonori Yano[2], Yusuke Tanigawara[5] and Kuniaki Shirao[1]

[1]Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, [2]Gastrointestinal Oncology & Endoscopy Division, National Cancer Center Hospital East, Kashiwa, Chiba, [3]Gastrointestinal Oncology & Endoscopy Division, Shizuoka Cancer Center Hospital, Suntoh-gun, Shizuoka, [4]Gastroentorology Division, Saku Central Hospital, Nagano and [5]Department of Pharmacy, Keio University, Tokyo, Japan

Received November 1, 2005; accepted December 27, 2005

Background: Infusional fluorouracil (5-FU) and leucovorin (LV) with oxaliplatin is one of the current standard regimens for the treatment of patients with metastatic colorectal cancer. Weekly bolus 5-FU with high-dose LV (Roswell Park Memorial Institute Regimen: RPMI) is the most commonly used regimen in Japan. The objectives of this study were to determine the recommended dose (RD) of RPMI combined with oxaliplatin and to evaluate the toxicity and efficacy at the RD.
Methods: The subjects were 18 patients with metastatic colorectal cancer. Oxaliplatin (85 mg/m^2) was given intravenously over 2 h on days 1 and 15 with *l*-LV (250 mg/m^2) given intravenously over 2 h and 5-FU as an intravenous bolus on days 1, 8, and 15. This treatment was repeated every 4 weeks. The dose of 5-FU was escalated from 400 mg/m^2 (level 1) to 500 mg/m^2 (level 2).
Results: A total of 14 patients received level 1, and 4 received level 2. Three of the patients had dose-limiting toxicity (DLT) in cycle 1 of level 2 (grade 3 thrombocytopenia, grade 4 neutropenia and grade 2 neutropenia in one patient each), requiring that treatment was delayed for longer than 7 days. None of the 14 patients given level 1 had DLT or grade 3 or 4 gastrointestinal toxicity. Sensory neuropathy occurred in all patients. Objective response rates were 61% in the 18 patients studied and 64% at level 1. The median time to progression was 171 days, and the median overall survival time was 603 days in the 18 patients studied.
Conclusions: Oxaliplatin (85 mg/m^2) with weekly bolus 5-FU (400 mg/m^2) and high-dose *l*-LV (250 mg/m^2) is recommended for further phase III studies in patients with metastatic colorectal cancer.

Key words: colorectal cancer – bolus 5-fluorouracil – leucovorin – oxaliplatin – RPMI

INTRODUCTION

Infusional fluorouracil (5-FU) and leucovorin (LV) with oxaliplatin is one of the current standard regimens for first- and second-line chemotherapy in patients with metastatic colorectal cancer (1–3). The combination of oxaliplatin with infusional 5-FU and LV (FOLFOX4) has been shown to be superior to infusional 5-FU plus LV (LV5FU2) and single-agent oxaliplatin in terms of response rate, median time to progression (TTP), and alleviation of tumor-related symptoms in patients with metastatic colorectal cancer who have disease progression after irinotecan with bolus 5-FU plus leucovorin (IFL, Saltz regimen) (2). Objective response rates were 9.9% for FOLFOX4, 1.3% for oxaliplatin alone and 0% for LV5FU2 ($P < 0.0001$). Median TTP was 4.6 months for FOLFOX4, 1.6 months for oxaliplatin and 2.7 months for LV5FU2 ($P < 0.0001$).

FOLFOX4 has also been evaluated as first-line therapy, and a randomized study (N9741) has shown a significantly better response rate, median TTP and median overall survival time (MST) as compared with conventional regimens (3). The response rate in patients given FOLFOX4 (45%) was higher than that in patients given IFL (31%, $P = 0.002$). Moreover, TTP was significantly longer with FOLFOX4 (8.7 months)

For reprints and all correspondence: Yasuhide Yamada, Gastrointestinal Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: yayamada@ncc.go.jp

than with IFL (6.9 months; $P = 0.0014$). The MST in patients treated with FOLFOX4 was 19.5 months as compared with only 15.0 months in those treated with IFL ($P = 0.0001$).

Infusional 5-FU regimens were shown by de Gramont (4) to provide a higher response rate with marginal survival benefit as compared with bolus 5-FU regimens. However, infusional 5-FU with LV has the drawbacks of increased inconvenience, cost and morbidity, related to the use of a portable infusion pump and a central venous catheter. Weekly bolus 5-FU with high-dose LV (RPMI regimen) is the most commonly used schedule in Japan and the United States, and bolus 5-FU plus low-dose LV with irinotecan (modified Saltz regimen) has been shown to have high antitumor activity with a favorable toxicity profile in Japanese patients (5–8). Single-agent oxaliplatin (130 mg/m^2) in a tri-weekly regimen has also been found to be effective and tolerable in Japanese as well as Western patients (9). Phase II studies of oxaliplatin as second-line therapy in patients with fluoropyrimidine-pretreated metastatic colorectal cancer reported objective response rates of 9–11% and an MST of 8.2–11.3 months (10–11). However, whether bolus 5-FU plus LV can be combined safely with oxaliplatin in Japanese patients remains unclear.

The primary objectives of this phase I/II study were to estimate the maximal tolerated dose (MTD) and determine the recommended dose of bolus 5-FU plus *l*-LV in combination with oxaliplatin. In the phase II part, we also evaluated the toxicity and antitumor activity of this regimen at the recommended dose.

PATIENTS AND METHODS

Patient Eligibility

Patients with histologically confirmed colorectal cancer who had measurable metastatic disease were eligible for the study. Prior chemotherapy and radiotherapy for metastatic disease were not permitted. Patients who had received adjuvant oral fluorouracil-based therapy were eligible if they had remained free of disease for at least 6 months after the completion of such therapy. Other eligibility criteria included an age of 20–75 years; an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; adequate baseline bone marrow function (white blood cell [WBC] count more than the lower limit of normal at each hospital and <12 000/μl, neutrophil count >2000/μl and platelet count >100 000/μl), hepatic function (serum bilirubin level 1.5 times the upper limit of normal or less, and serum aspartate aminotransferase and alanine aminotransferase 2.5 times the upper limit of normal or less) and renal function (serum creatinine level 1.5 times the upper limit of normal or less); and a life expectancy of at least 12 weeks. All patients gave written informed consent.

Patients were excluded if they had symptomatic brain metastasis; pre-existing watery diarrhea; concomitant nonmalignant disease, such as cardiac, pulmonary, renal or hepatic disease; or uncontrolled infection. This study was approved by the institutional review board of each center. Before enrollment, all patients underwent a physical examination (including documentation of measurable disease), a complete blood cell count with differential count, serum chemical analysis, chest radiography, electrocardiography, and computed tomographic (CT) scanning or magnetic resonance imaging (MRI).

Toxicity and Response Criteria

Toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria, Version 2.0 (NCI-CTC) (12). Neurotoxicity was reported according to the following grading scale: grade 1, dysesthesia or paresthesia that completely regressed within 6 days; grade 2, dysesthesia or paresthesia persisting for 7 days or longer; and grade 3, dysesthesia or paresthesia causing functional impairment. During the study, all patients were evaluated weekly for signs and symptoms of toxicity. Complete blood cell counts including differential count; liver function tests; measurement of urea nitrogen, creatinine and electrolyte levels; and urinalysis were performed weekly in cycle 1 and every 2 weeks in subsequent cycles.

The response of measurable and assessable disease sites was evaluated according to RECIST (Response Evaluation Criteria in Solid Tumors) (13). Tumor dimensions were assessed by CT scanning or MRI every month to confirm response and every 2 months subsequently. Partial response (PR) was defined as more than a 30% decrease in the sum of the products of the greatest perpendicular diameters of measurable lesions, without the development of any new lesions. Stable disease was defined as a steady state of response less than a PR or as progression of <20% over the course of at least 6 weeks. Progressive disease (PD) was defined as an unequivocal increase of at least 20% in the sum of the products of the greatest perpendicular diameters of individual lesions. The appearance of new clinically significant lesions also constituted a PD.

Treatment Plan

Oxaliplatin was supplied as a freeze-dried powder in 100 mg vials by Yakult Honsha Co., Ltd. (Tokyo, Japan) and was reconstituted in a solution of 5% glucose in water. The reconstituted solution was then diluted with 250 ml of 5% glucose infusion solution. Oxaliplatin was administered as a 2 h infusion every 2 weeks. The duration of infusion could be extended to 6 h in patients who had pharyngolaryngeal dysesthesia during infusion. *l*-Leucovorin (Wyeth Ltd., Tokyo, Japan) was administered at a dose of 250 mg/m^2 in 500 ml of 5% glucose solution, given as a 2 h intravenous infusion on days 1, 8 and 15 of a 28 day cycle. 5-FU (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan) was given by bolus intravenous injection 1 h after starting the *l*-LV infusion. All patients received premedication with a 5-hydroxytryptamine-3-receptor antagonist with or without dexamethasone, given as a 30 min drip infusion before chemotherapy. Treatment cycles were repeated every 4 weeks. Treatment was routinely given on an outpatient basis, except for cycle 1 of the dose-escalation portion of the protocol (see below). Subsequent treatment was withheld until the

WBC, neutrophil,and platelet counts were >3000, 1500 and 75 000 μl, respectively, and diarrhea, stomatitis and hand-foot syndrome had resolved to grade 0 or 1. Treatment was repeated until the onset of disease progression or severe toxicity.

Dose-Escalation Schedule

The dose of oxaliplatin was fixed at 85 mg/m^2 and that of *l*-LV was fixed at 250 mg/m^2. 5-FU was studied in dose levels of 400 and 500 mg/m^2. A minimum of three patients were studied per dose level. Dose-limiting toxicity (DLT) was defined as any of the following findings during cycle 1: (i) a neutrophil count of <500/μl, (ii) grade 3 febrile neutropenia, (iii) a platelet count of <50 000/μl, (iv) grade 3 or 4 non-hematologic toxicity, excluding nausea, anorexia, and electrolyte imbalance according to the NCI-CTC, or (v) a longer than 1 week delay in treatment as a result of drug-related toxicity in the dose-escalation portion of the protocol. If DLT occurred in 1 of the first 3 patients assigned to a given dose level, 3 other patients were additionally assigned to receive that dose level. The MTD was defined as the dose that induced DLT during cycle 1 in at least 50% of the subjects. In the second portion of the study, the recommended dose was given to 11 other patients to confirm tolerability.

The dose was modified for each patient according to a nomogram, based on hematologic or non-hematologic toxicity. If DLT occurred, the subsequent dose of oxaliplatin was reduced to 75% of the initial dose and that of 5-FU was decreased by one dose level. If the WBC count on days 8, 15 and 22 was <3000/μl, the neutrophil count <1500/μl, or the platelet count <75 000/μl, further treatment was delayed for up to 1 week until recovery. Recombinant granulocyte colony-stimulating factor was subcutaneously injected if patients had grade 4 neutropenia or grade 3 febrile neutropenia, but prophylactic use was not allowed.

RESULTS

Patient Characteristics

From March 2002 to March 2003, a total of 18 patients were enrolled. All patients received at least one cycle of the study treatment. The first 7 patients participated in the dose-escalation portion of the protocol. After identification of the MTD, 11 other patients received the recommended dose below the MTD to further evaluate the tolerability and toxicity of the study regimen. The patient characteristics are summarized in Table 1. Two patients had received adjuvant oral fluorouracil-based therapy.

Toxicity

No DLT occurred during cycle 1 in the first 3 patients given a dose of 400 mg/m^2 of 5-FU. Two of the 3 patients initially treated with 500 mg/m^2 of 5-FU had dose-limiting myelosuppression. One patient had grade 3 thrombocytopenia, and the other had prolonged grade 2 neutropenia, requiring that

Table 1. Patient characteristics

Characteristic	Level 1 (n = 14)		Level 2 (n = 4)	
	No. of patients	(%)	No. of patients	(%)
Age (years)				
Median	60.0		67.5	
Range	37–68		55–73	
Sex				
Male	8	57	3	75
Female	6	43	1	25
ECOG performance status				
0	12	86	3	75
1	2	14	1	25
Primary tumor				
Colon	9	64	4	100
Rectum	5	36	0	0
Metastatic site*				
Liver only	8	57	2	50
Lung only	2	14	0	0
Others	4	29	2	50
No. of metastatic sites				
1	13	93	3	75
≥2	1	7	1	25

Abbreviation: ECOG, Eastern Cooperative Oncology Group.
*Target lesion according to RECIST criteria.

Table 2. Toxicity, worst grade per patient

Level	1 (n = 14)					2 (n = 4)				
Dose of 5-FU	400 mg/m^2					500 mg/m^2				
	Grade					Grade				
	1	2	3	4	1–4 (%)	1	2	3	4
Anorexia	8	6	0	0	100	1	1	1	0
Nausea	8	3	0	0	79	2	1	0	0
Vomiting	4	5	0	0	64	3	0	0	0
Diarrhea	4	3	0	0	50	1	2	0	0
Stomatitis	3	2	0	0	36	0	0	0	0
Fatigue	7	1	0	0	57	2	0	0	0
Injection site reaction	8	3	0	0	79	3	0	0	0
Allergic reaction	1	1	0	0	14	0	0	0	0
Sensory neuropathy	0	14	0	–	100	0	4	0	–
Alopecia	1	0	–	–	7	2	0	–	–
Neutropenia	5	4	2	0	79	0	2	1	1
Leukopenia	2	4	0	0	43	0	4	0	0
Thrombocytopenia	6	4	0	0	71	1	1	2	0
AST elevation	5	3	0	0	57	2	0	0	0
ALT elevation	3	6	0	0	64	2	0	0	0

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Table 3. Objective response

	No. of patients	PR	SD	PD	Response rate (%) (95% CI)
Level 1 5-FU 400 mg/m^2	14	9	5	0	64 (35–87)
Level 2 5-FU 500 mg/m^2	4	2	2	0	50 (7–93)
All patients	18	11	7	0	61 (36–83)

Abbreviations: PR, partial response; SD, stable disease; PD, progressive disease; CI, confidence interval

treatment was delayed for longer than 1 week. The fourth patient given 5-FU 500 mg/m^2 had grade 4 neutropenia. DLT thus comprised neutropenia and thrombocytopenia. The recommended dose was determined to be 400 mg/m^2 of 5-FU in combination with 250 mg/m^2 of *l*-LV and 85 mg/m^2 of oxaliplatin (Table 2).

Eleven patients were subsequently enrolled in the second portion of this study.

Combined with the 3 initially treated patients, a total of 14 patients received the recommended dose. The median number of administered cycles was 5.5 (range, 2–11), and the total number of cycles in the 14 patients was 74. At the recommended dose, 2 patients (14%) had grade 3 neutropenia; there was no grade 4 toxicity. The relative dose intensity was 82.5% for oxaliplatin and 84.9% for 5-FU during the first 6 cycles. The causes of treatment discontinuation at the recommended dose were PD in 8 patients, almost a complete response in 1, delayed recovery from thrombocytopenia in 2 and sensory neuropathy in 3.

Sensory neuropathy occurred in all patients. There was no neurotoxicity with functional impairment in this study. The most common types of non-hematologic toxicity were anorexia, nausea, vomiting and diarrhea. No patient had grade 3 or 4 gastrointestinal toxicity at the recommended dose. Most cases of nausea and vomiting responded to dexamethasone and granisetron or other antiemetic drugs, and good oral intake was maintained. Another mild adverse event related to treatment was injection site reactions (79%). Two patients had mild allergic reactions such as skin rash or fever, typical platinum-related reactions.

Response to Therapy

The objective tumor response was determined by an external review board. Of the 14 patients given the recommended dose (level 1) 9 had a PR, yielding a response rate of 64% (95% CI: 35–87%). One of 9 responders underwent hepatectomy following this chemotherapy. Two of the 4 patients given level 2 had a PR. In the 18 patients studied, the response rate was 61% (95% CI: 36–83%), the median time to progression was 171 days (95% CI: 142–227 days) and the median overall survival time (cut-off date: March 27, 2005) was 603 days (95% CI: 442–979 days) (Fig. 1). The 1-year and 2-year survival rates were 94 and 31%, respectively.



Figure 1. Overall survival in all patients.

DISCUSSION

Our results suggest that bolus 5-FU plus *l*-LV with oxaliplatin may be a safe and effective first-line treatment for metastatic colorectal cancer. The recommended dose was determined to be 400 mg/m^2 of 5-FU plus 250 mg/m^2 of *l*-LV on days 1, 8 and 15 with 85 mg/m^2 of oxaliplatin on days 1 and 15 of a 28 day cycle. DLT comprised neutropenia and thrombocytopenia at level 2. At the recommended dose (level 1), the toxicity profile was acceptable, with grade 3 neutropenia occurring in 14% of the patients; there was no other grade 3 or 4 hematologic or non-hematologic toxicity, including neurotoxicity (table3).

Two consecutive compassionate-use studies of oxaliplatin were conducted in North America until December 2000 in more than 5000 patients with metastatic colorectal cancer who had had treatment failure with at least 1 prior chemotherapy regimen (14). Patients were assigned to treatment with either single-agent oxaliplatin or oxaliplatin plus 5-FU with or without LV in various regimens. The most frequently used regimen was RPMI with oxaliplatin, received by 43–45% of the patients in both studies. Continuous infusion of low-dose 5-FU (Lokich regimen) was given to 14–20% of the patients, a modified Mayo regimen to 9–15% and LV5FU2 to only 8–10%. US and Canadian oncologists have preferred bolus regimens in combination with oxaliplatin, despite the availability of infusion schedules. The incidence of grade 3 and 4 hematologic toxicity was 17% with RPMI plus oxaliplatin and 52% with FOLFOX4 and that of grade 3 and 4 gastrointestinal toxicity was 28% with RPMI and 18% with FOLFOX4. Neurological toxicity occurred at a rate of 2% with RPMI and 8% with FOLFOX4.

Hochster et al. (15) reported the results of phase II studies of weekly bolus 5-FU (500 mg/m^2, days 1, 8 and 15, every 4 weeks) plus low-dose LV (20 mg/m^2, days 1, 8 and 15, every 4 weeks) with oxaliplatin (85 mg/m^2, days 1 and 15, every 4 weeks) (bFOL), given as first-line therapy to patients with metastatic colorectal cancer. The response rate was 63%, with a median TTP of 9.0 months and an MST of 15.9 months. Common toxicity included grade 3 and 4 neutropenia in 10% of patients, grade 3 and 4 diarrhea in 29%, and grade 3 cumulative neuropathy in 12%. Welles et al. (16) reported the results of a randomized phase II study assessing the safety and tolerability of 3 oxaliplatin-based regimens as first-line

treatment for advanced colorectal cancer ('TREE 1' study). One arm was bFOL; the other 2 arms were modified FOLFOX6 (oxaliplatin 85 mg/m^2, LV 350 mg, 5-FU bolus 400 mg/m^2 and infusional 2400 mg/m^2 over the course of 46 h, every 2 weeks) and CapeOx (oxaliplatin 130 mg/m^2 on day 1 and oral capecitabine 1000 mg/m^2 twice daily for 14 days, every 3 weeks). The primary endpoint was the overall incidence of grade 3 and 4 toxicity during the first 12 weeks of each study therapy, and secondary endpoints were overall response rate and TTP. The overall incidence of grade 3 and 4 toxicity was significantly higher with modified FOLFOX6 (mFOLFOX6) (77%) than with bFOL (44%, $P < 0.001$). Moreover, mFOLFOX6 (37%) had a significantly higher incidence of grade 3 and 4 neutropenia than bFOL (14%, $P < 0.01$) and CapeOx (8%) ($P < 0.001$). Grade 3 and 4 diarrhea occurred in similar proportions of patients given bFOL (22%), mFOLFOX6 (22%) or CapeOx (25%). The overall response rate did not significantly differ among the 3 arms and was 52% (21/40) with mFOLFOX6, 38% (14/37) with bFOL and 50% (17/34) with CapeOx. Median times to discontinuation of study therapy were 5.7 months with mFOLFOX6, 4.8 months with bFOL and 4.2 months with CapeOx. These results suggested that bFOL is as active and safe as the other two regimens.

Other schedules of bolus 5-FU and low-dose LV (Mayo Clinic regimen) with oxaliplatin have also been investigated. Zori Comba et al. (17) reported the results of a phase II study of the Mayo Clinic regimen (5-FU 425 mg/m^2, days 1–5, every 4 weeks) plus low-dose LV (20 mg/m^2, days 1 to 5, every 4 weeks) with oxaliplatin (85 mg/m^2, days 1 and 15, every 4 weeks) in previously untreated patients with metastatic colorectal cancer. The response rate was 45%, with a median TTP of 3.9 months. Grade 3 and 4 neutropenia occurred in 23% of the patients, diarrhea in 34%, vomiting in 14% and stomatitis in 14%. This regimen was unacceptable because of the high incidence of severe toxicity. Ravaioli et al. (18) used the Machover scheme (5-FU 350 mg/m^2, days 1–5, every 3 weeks) and low-dose LV (20 mg/m^2, days 1–5, every 3 weeks) with oxaliplatin (130 mg/m^2, day 1, every 3 weeks) as first-line treatment for metastatic colorectal cancer. The response rate was 40%, with a median TTP of 5.9 months and an MST of 14 months. Grade 3 or severer neutropenia or diarrhea occurred in 20 and 29% of the patients, respectively. Sørbye et al. (19) performed a phase II study of Nordic bolus 5-FU (500 mg/m^2, days 1 and 2, every 2 weeks) and low-dose LV (60 mg/m^2, days 1 and 2, every 2 weeks) with oxaliplatin (85 mg/m^2, day 1, every 2 weeks) (Nordic FLOX), given as first-line therapy to patients with metastatic colorectal cancer. The response rate was 62% with a median TTP of 7.0 months and an MST of 16.1 months. Common toxicity included grade 3 and 4 neutropenia in 58% of patients, grade 3 and 4 diarrhea in 7%, and grade 3 cumulative neuropathy in 13%. Febrile neutropenia developed in 8%. That study concluded that Nordic FLOX is an effective and feasible regimen, despite the high incidence of neutropenia.

In our study, the most frequent types of non-hematologic toxicity were mild anorexia, nausea, vomiting, fatigue and diarrhea. Grade 3 neutropenia occurred in only 14% of our patients at the recommended dose. Our regimen was active and safe and may thus be a new alternative treatment for metastatic colorectal cancer. Further clinical phase II/III studies should compare RPMI plus oxaliplatin with FOLFOX to more objectively confirm our findings before our regimen is widely used clinically.

Acknowledgments

We are grateful to Drs H. Furue, T. Taguchi, Y. Sakata, Y. Sasaki, H. Takiuchi and F. Nagamura for their kind advice and to Drs. A. Sato, K. Yoshikawa, K. Miyakawa, who performed the external review board. We also thank S. Sugimoto, N. Sekine, T. Miyazaki, M. Matsuo and H. Ogawa for their assistance in data management. This study was supported by Yakult Honsha Co., Ltd., Tokyo.

References

1. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 2000;18:2938–47.
2. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. *J Clin Oncol* 2003; 21:2059–69.
3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2004:22:23–30.
4. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. *J Clin Oncol* 1997;15:808–15.
5. Yoshino M, Ota K, Kurihara M, Akazawa S, Tominaga T, Sasaki T, et al. Late phase II trial of high-dose l-leucovorin and 5-fluorouracil in advanced colorectal carcinoma. l-Leucovorin and 5-FU Study Group (Japan Eastern Group). *Jpn J Cancer Chemother* 1995;22:785–92 (in Japanese).
6. Konishi K, Yabushita K, Taguchi T, Ota J, Takashima S, Abe T, et al. A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group). *Jpn J Cancer Chemother* 1995;22:925–32 (in Japanese).
7. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. *J Clin Oncol* 1996;14:2959–67.
8. Goto A, Yamada Y, Hosokawa A, Ura T, Arai T, Hamaguchi T, et al. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. *Int J Clin Oncol* 2004;9:364–8.
9. Shirao K, Matsumura Y, Yamada Y, Muro K, Gotoh M, Boku N, et al. Tolerability and pharmacokinetic profile of oxaliplatin in Japanese solid tumor patients. *Proc ASCO* 2001;20: 94b (abstr 2124).
10. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. *Ann Oncol* 1996;7:95–8.
11. Hyodo I, Shirao K, Boku N, Ohtsu A, Miyata Y. Nakagawa K, et al. Phase II trial and pharmacokinetic analysis of oxaliplatin (L-OHP) as second-line treatment in patients (pts) with metastatic colorectal cancer (MCRC). *Proc ASCO* 2003;22:344 (abstr 1383).

12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Center Institute of Canada. *J Natl Cancer Inst* 2000; 92:205–16.
13. Shimoyama M. The Japanese edition of the National Cancer Institute—common toxicity criteria. *Jpn J Cancer Chemother* 1999;26:1084–144 (in Japanese).
14. Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gococo KO, Hallar DG, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. *J Clin Oncol* 2003;21:2904–11.
15. Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. *J Clin Oncol* 2003; 21:2703–7.
16. Welles L, Hochster H, Ramanathan R, Wong L, Hart L, Shpilsky A, et al. Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) ('Tree' study). *Proc ASCO* 2004;23:254 (abstr 3537).
17. Zori Comba A, Blajman C, Richardet E, Bella S, Vilanova M, Coppola F, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. *Eur J Cancer* 2001;37:1006–13.
18. Ravaioli A, Marangolo M, Pasquini E, Rossi A, Amadori D, Cruciani G, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. *J Clin Oncol* 2002;20:2545–50.
19. Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2004;22:31–8.

実地臨床におけるFOLFOX療法，およびFOLFIRI療法の現状

——第一報——

北信癌化学療法談話会

工藤道也[1*]・池野龍雄[2]・川手裕義[3]
熊木俊成[4]・袖山治嗣[5]・藤森芳郎[6]
宮田佳典[7]・宗像康博[8]

1：NTT東日本長野病院外科　2：JA長野厚生連篠ノ井総合病院外科　3：JA長野厚生連新町病院外科
4：JA長野厚生連長野松代総合病院外科　5：長野赤十字病院外科　6：JA長野厚生連北信総合病院外科
7：JA長野厚生連佐久総合病院胃腸科　8：長野市民病院外科

「新薬と臨牀」第55巻第9号別冊
（平成18年9月10日発行）
医薬情報研究所

実地臨床におけるFOLFOX療法，およびFOLFIRI療法の現状

──第一報──

北信癌化学療法談話会

工藤 道也[1*]・池野 龍雄[2]・川手 裕義[3]
熊木 俊成[4]・袖山 治嗣[5]・藤森 芳郎[6]
宮田 佳典[7]・宗像 康博[8]

要　旨

長野県北部，および東部地区の一般病院における進行大腸癌に対するFOLFOX療法，およびFOLFIRI療法について約1年間の成績をまとめた。対象はFOLFOX39例，FOLFIRI15例で，初回治療としてFOLFOX療法を行った群の奏効率は50.0%（11/22）であった。FOLFOX療法によるGrade 3以上の有害事象発現率は初回治療群で19.2%（5/26），二次治療群で70.6%（12/17）．最も多かった有害事象は血液障害（白血球減少14例，血小板減少1例）であり，他に意識障害1例，食欲不振1例を認めた。Grade 3以上の末梢神経障害はなかった。一方，FOLFIRI療法によるGrade 3以上の有害事象発現率は初回治療群で60.0%（6/10），二次治療群では40.0%（2/5）であった。最も多かった有害事象は白血球減少6例であり，他にDIC 1例と脳梗塞1例を認めた。

はじめに

2005年は本邦での大腸癌化学療法に大きな変化があった。まず2月に切除不能進行・再発大腸癌に対しレボホリナート（商品名：アイソボリン®，以下ℓ-LV）・フルオロウラシル（5-FU）持続静注併用療法（de Gramont[1]，sLV5FU2[2]，AIO[3]レジメン）が承認された[4]。これによりCPT-11との併用でFOLFIRI療法[5]が施行可能になった。さらに，4月にはオキ

1：NTT東日本長野病院外科　2：JA長野厚生連篠ノ井総合病院外科　3：JA長野厚生連新町病院外科
4：JA長野厚生連長野松代総合病院外科　5：長野赤十字病院外科　6：JA長野厚生連北信総合病院外科
7：JA長野厚生連佐久総合病院胃腸科　8：長野市民病院外科

表1　集積全症例（n=118）

	FOLFOX (n=77)	FOLFIRI (n=41)	計
初回治療	26 (33.8)	10 (24.4)	36 (30.5)
二次治療	17 (22.1)	5 (12.2)	22 (18.6)
三次治療～	34 (44.2)	26 (63.4)	60 (50.8)

(%)

サリプラチン（商品名：エルプラット®，以下L-OHP）が前述のℓ-LV/5-FU持続レジメンとの併用で承認され，FOLFOX療法[5]が施行可能になった。

今回FOLFOX療法，およびFOLFIRI療法の施行が可能になって約1年が経過したことから，北信癌化学療法談話会幹事施設および診療科において実施された各療法の有効性，有害事象について後ろ向き解析を行った。

I　対象および方法

1．対象

2005年3月から2006年3月までに当会幹事施設において進行大腸癌に対しFOLFOX療法，またはFOLFIRI療法が施行された症例は計118例であった。このうち，初回治療，または二次治療として施行された58例を今回の有効性，有害事象についての評価対象とした（表1）。なお，初回治療としてFOLFOX療法を行った症例のうち4例は評価に至らず，評価対象は54例であった。

2．投与方法

本邦で施行可能なFOLFOX療法には，FOLFOX4 regimen[6]とmFOLFOX6 regimenの2つの投与方法がある。FOLFOX4 regimenは2週間に1度，2日間かけて行う方法であり，day 1にℓ-LV 100mg/m²とL-OHP 85mg/m²を2時間で静注後，5-FU 400mg/m²をbolus，さらに5-FU 600mg/m²を22時間で持続点滴し，day 2にはL-OHPを除きday 1と同じ投与を繰返す方法である。mFOLFOX6 regimenはこれを簡略化したもので，ℓ-LV 200mg m²とL-OHP 85mg/m²を2時間で静注後，5-FU 400mg/m²をbolus，さらに5-FU 2400～3000mg/m²を46時間で持続点滴する方法である（図1）。今回FOLFOX4 regimenが3例に，mFOLFOX6 regimenが40例に施行されていた。なお，L-OHPの末梢神経障害を予防するために，原則としてL-OHP投与の前後にCa，Mg製剤が投与[7][8]されていた（図2）。

代表的なFOLFIRI regimenの投与方法は，mFOLFOX6 regimenのL-OHPの部分をCPT-11 150～180mg/m²の90分点滴に代えて，ℓ-LVと同時に投与を開始するものである（図1）。

なお，FOLFOX療法，FOLFIRI療法の投与は原則として中心静脈ポートの埋込みで行われている。

3．評価・確認項目

以下について評価を行った。

・症例数，患者背景
・二次治療群における前治療
・投与法，初回治療，二次治療毎の有効性
・有害事象

なお，治療効果はRECISTガイドライン[9]の判定基準に準拠した。また，有害事象の評価にはCTCAE v3.0日本語訳JCOG/JSCO版[10]を用いた。ただし，末梢神経障害についてはDEBNTC（Neurotoxicity criteria of DEBIOPHARM）[11]で判定した（表2）。



図1　本邦で施行可能なFOLFOX, FOLFIRI の投与スケジュール



図2　末梢神経障害対策（例）

表2　知覚異常/感覚異常の評価

CTCAE v3.0
G1：症状がない；深部腱反射消失または知覚異常（疼きを含む）があるが機能障害はない
G2：知覚変化または知覚異常（疼きを含む）による機能障害はあるが，日常生活に支障がない
G3：日常生活に支障がある知覚変化または知覚異常
G4：活動不能，動作不能
DEB-NTC
G0：異常なし
G1：末梢神経症状の発現。ただし7日未満で消失
G2：7日以上持続する末梢神経症状。ただし機能障害はない
G3：機能障害の発現

表3　解析症例の内訳

		FOLFOX	FOLFIRI
No. of Pts		39	15
age, years	median (range)	61 (26-83)	67 (49-75)
sex	F/M	19/20	4/11
PS	0/1/2/3	20/16/2/1	10/4/0/1
location	C/A/T/D/S/R	3/2/4/0/10/20	1/3/2/1/5/3
cycle	median (range)	6 (2-14)	7 (1-21)

Ⅱ　結　　果

1．症例数，患者背景

集積された全症例はFOLFOX77例，FOLFIRI41例の合計118例（表1）であった。その内訳は初回治療36例（30.5%）二次治療22例（18.6%）三次治療以降60例（50.8%）であり，FOLFOX症例の44.2%，FOLFIRI症例の63.4%は三次治療以降であった。

初回治療または二次治療として施行した症例は58例であったが，FOLFOX症例のうち初回治療の4例が評価に至らず，評価可能症例はFOLFOX症例39例，FOLFIRI症例15例の計54例であった（表3）。FOLFOX症例のPerformance Status（PS）は2例を除いて0～2であった。PS3の2例は本人および家族の強い希望があり施行した。

2．二次治療群における前治療

二次治療としてFOLFOX療法またはFOLFIRI療法が施行された22例について，その前治療を確認した（表4）。FOLFOX症例の前治療はFOLFIRIが1例，IFL[12)13)]が6例，RPMI[14)]が4例，UFT/LV[15)]が5例，その他が1例であった。FOLFIRI症例の前治療ではRPMIが3例，UFT/LVが1例，その他が1例であった。

3．有効性

初回治療としてFOLFOX療法を施行した症例の奏効率は50.0%（11/22）であり，SD症例まで含めると86.4%（19/22）の腫瘍制御率であった。二次治療群での奏効率は23.5%（4/17）と初回治療群の半分以下であったが，SD症例

表4　二次治療群における前治療の内訳

	FOLFOX (n=17)	FOLFIRI (n=5)
FOLFOX		0
FOLFIRI	1	
IFL	6	0
RPMI	4	3
UFT/LV	5	1
other	1	1

表5　FOLFOX，FOLFIRI療法の成績

	FOLFOX (n=39)		FOLFIRI (n=15)	
	奏効率	腫瘍制御率	奏効率	腫瘍制御率
初回治療	50.0% (11/22) CR 2 /PR 9	86.4% (19/22) SD 8 (PD 3)	40.0% (4/10) CR 1 /PR 3	50.0% (5/10) SD 1 (PD 5)
二次治療	23.5% (4/17) CR 0 /PR 4	76.5% (13/17) SD 9 (PD 4)	20.0% (1/5) CR 0 /PR 1	60.0% (3/5) SD 2 (PD 2)

が9例と多く，腫瘍制御率は76.5% (13/17) であった。一方，初回治療としてFOLFIRI療法を施行した症例での奏効率は40.0% (4/10)，腫瘍制御率は50.0% (5/10) であった（表5）。

4．有害事象

FOLFOX療法におけるGrade 3 以上の有害事象発現率は，初回治療群で19.2% (5/26) であったのに対し，二次治療群では70.6% (12/17) であった。L-OHPまたは5-FUを減量されている症例は初回治療群で30.8% (8/26)，二次治療群では52.9% (9/17) であった。

FOLFOX療法について最も多かった有害事象は，白血球減少14例であった。他に血小板減少1例，意識障害1例，食欲不振1例が認められた。また，Grade 3 以上の末梢神経障害は認められなかった。

一方，FOLFIRI療法でのGrade 3 以上の有害事象発現率は初回治療群で60.0% (6/10)，二次治療群では40.0% (2/5) であった。CPT-11または5-FUが減量されている症例は初回治療群，二次治療群ともに各1例であった。最も多かった有害事象は白血球減少6例であり，他にDIC 1 例と脳梗塞1例が認められた。なおFOLFOX療法，FOLFIRI療法ともに治療関連死はなかった（表6）。

5．まとめ

当会の幹事施設および診療科において約1年の間にFOLFOX療法，またはFOLFIRI療法が施行された症例について検討した。全体の約半数が三次治療以降の症例であったが，今回は初回治療と二次治療の有効性と有害事象を確認した。初回治療と二次治療での治療法の選択は，FOLFOX療法がFOLFIRI療法の3倍近く行われていた。今回の集積は2005年3月からであったが，二次治療症例での前治療は，ほとんどの症例は大腸癌治療ガイドライン[16]で推奨されている治療法の範囲（RPMI 7例，IFL 6例，UFT/LV 6例，FOLFIRI 1例，